The US Food and Drug Administration (FDA) has revealed its decision to grant a priority review for the Bayer pulmonary arterial hypertension riociguat.

The New Drug Application for riociguat was filed by Bayer in February on both sides of the Atlantic for PAH and inoperable chronic thromboembolic pulmonary hypertension.

It was in 2011 that a specific age limit was set by the US Government for girls for the sales of emergency contraception pills.

The age set for girls was 17 and they needed to show identity proof confirming their age before they could purchase the pills. It is now that a federal judge in New York has asked the Food and Drug Administration to lift the age barrier.

As per recent reports, it has been revealed that temporary tattoos have been found to be dangerous for health. The Food and Drug Administration has raised concerns about the same and has issued warning about the temporary tattoos.

The Food and Drug Administration called on an antibiotic, azithromycin, after a study revealed the potential risks to alter electrical activity of the heart. The drug is a commonly used antibiotic for bacterial infections including, bronchitis, pneumonia, sore throats and earaches.

Women in their menopausal stages had been in need of alternative medicines to treat hot flashes from a long time. Food and Drug Administration (FDA) has not provided a solution rather it has rejected two drugs that were meant to resolve the issue.

The USA Food and Drug Administration (FDA) has permitted the cancer drug, Stivarga (regorafenib), for the treatment for advanced gastrointestinal stromal tumors (GIST).

Richard Pazdur M. D., the director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, said that this drug is the third medication used in the treatment of GIST.